Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.
100% less funds holding
Funds holding: 200 → 1 (-199)
100% less funds holding in top 10
Funds holding in top 10: 10 → 0 (-10)
100% less capital invested
Capital invested by funds: $2.73B → $21.1K (-$2.73B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 198
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$262M |
| 2 |
BlackRock
New York
|
-$227M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$164M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$149M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$144M |
CBAY Hedge Fund Activity: Q1 2024 in Review
1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.
Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.
- 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
- Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
- The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.
Based on aggregated 13F filings for Q1 2024.